Live from ASH 2023 | Ascentage Pharma Presents Updated Data

SUZHOU, China, and ROCKVILLE, Md., Dec. 10, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data from a US study of the company's novel drug candidate, olverembatinib (R&D code: HQP1351), in patients with refractory chronic...

Related Keywords

San Diego , California , United States , Hong Kong , Philadelphia , Pennsylvania , Beijing , China , Suzhou , Jiangsu , Texas , Australia , Rockville , American , Chinese , Yifan Zhai , Ascentage Pharma , Elias Jabbour , Department Of Leukemia , Major National , American Society Of Hematology , China National Medical Products Administration , Md Anderson Cancer Center , University Of Texas Md Anderson Cancer Center , Dana Farber Cancer Institute , Astrazeneca , National Reimbursement Drug List , Poster Presentation , American Society , Annual Meeting , Oral Presentations , Doral Report , Cancer Center , Principal Investigator , Chief Medical Officer , Overcoming Ponatinib , Asciminib Resistance , Refractory Chronic Myeloid Leukemia , Myeloid Leukemia , Pacific Time , Beijing Time , Main Board , Stock Exchange , Hong Kong Limited , Major National Rd Projects , Major New Drug Projects , New Drug Incubator , Innovative Drug Programs , Major Project , Priority Review Designations , Breakthrough Therapy Designations , Drug Evaluation , Reimbursement Drug List , Orphan Drug Designation , Fast Track Designation , Orphan Designation , Pediatric Disease , Mayo Clinic ,